Pluripotent Stem Cell Differentiation into Hematopoietic Lineage Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for directed differentiation of pluripotent stem cells into hematopoietic lineage cells, such as NK cells, are inefficient and often require serums that pose risks of contamination and immune rejection, with challenges in producing high numbers of cells with consistent phenotype and functionality.
Innovation Solution
A method involving a series of culture media steps using a basal medium supplemented with nicotinamide, heparin, and human platelet lysate, along with Wnt signaling pathway activators and inhibitors, to promote the differentiation of pluripotent stem cells into hematopoietic lineage cells, including NK cells, while avoiding xenogenic contamination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current directed differentiation protocols are used, then hematopoietic lineage cells can be produced, but the efficiency is low and the phenotype/functionality consistency is poor
Solution Approach 1:
The differentiation process is divided into distinct stages with specific culture conditions for each: mesoderm induction stage, hemogenic endothelium stage, and hematopoietic progenitor stage. Each stage uses optimized culture media with specific growth factors and supplements to guide cells through sequential differentiation steps, improving both efficiency and consistency of the final NK cell product
Solution Approach 2:
The protocol systematically changes cultural parameters including growth factor concentrations (SCF, IL-3, IL-7, FLT3L), media composition, and oxygen levels at different differentiation stages. These parameter optimizations at each stage ensure high efficiency while maintaining consistent phenotype and functionality of the produced NK cells
2Reliability
If serums are used in culture media, then cell growth is supported, but the risk of contamination and immune rejection increases
Solution Approach 1:
The protocol completely removes serum components from the culture media, replacing them with chemically defined supplements including human platelet lysate, insulin-transferrin-selenium, and specific growth factors. This extraction of harmful serum components eliminates the risk of xenogenic contamination and immune rejection while maintaining high cell production efficiency through optimized supplement formulations
Solution Approach 2:
The protocol uses disposable, chemically defined culture media components that can be precisely controlled and replaced, eliminating the need for batch-to-batch serum testing and reducing contamination risks while maintaining reliable cell production
Data Source
AI summary
The present disclosure provides, inter alia, methods and compositions for differentiation of pluripotent stem cells and derived hematopoietic lineage cells including hemogenic endothelial cells, hematopoietic progenitor cells and natural killer cells. The differentiation efficiency for the hemogenic endothelial cells, the hematopoietic progenitor cells and the natural killer cells can be improved by using the methods and compositions of this disclosure described herein.